Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

BACKGROUND This study used CT imaging analyzed with deep learning techniques to assess the diagnostic accuracy of lung metastasis detection in patients with breast cancer. The aim of the research was to create and verify a system for detecting malignant and metastatic lung lesions that uses YOLOv10 and transfer learning. MATERIAL AND METHODS From January 2023 to 2024, CT scans of 16 patients with breast cancer who had confirmed lung metastases were gathered retrospectively from Erzincan Mengücek Gazi Training and Research Hospital. The YOLOv10 deep learning system was used to assess a labeled dataset of 1264 enhanced CT images. RESULTS A total of 1264 labeled images from 16 patients were included. With an accuracy of 96.4%, sensitivity of 94.1%, specificity of 97.1%, and precision of 90.3%, the ResNet-50 model performed best. The robustness of the model was shown by the remarkable area under the curve (AUC), which came in at 0.96. After dataset tuning, the GoogLeNet model's accuracy was 97.3%. These results highlight our approach's improved diagnostic capabilities over current approaches. CONCLUSIONS This study shows how YOLOv10 and transfer learning can be used to improve the diagnostic precision of pulmonary metastases in patients with breast cancer. The model's effectiveness is demonstrated by the excellent performance metrics attained, opening the door for its application in clinical situations. The suggested approach supports prompt and efficient treatment decisions by lowering radiologists; workload and improving the early diagnosis of metastatic lesions.

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.948195DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
yolov10 transfer
12
transfer learning
12
patients breast
12
lung metastases
8
diagnostic accuracy
8
deep learning
8
learning
5
early detection
4
lung
4

Similar Publications

Introduction: Cutaneous scalp metastases from breast carcinoma (CMBC) represent an uncommon manifestation of metastatic disease, with heterogeneous clinical presentations, including nodular or infiltrative lesions and scarring alopecia (alopecia neoplastica). The absence of standardized diagnostic criteria, particularly for alopecic phenotypes, poses challenges to early recognition of CMBC, which may represent either the first indication of neoplastic progression or a late recurrence.

Materials And Methods: We retrospectively analyzed a multicenter cohort of 15 patients with histologically confirmed CMBC.

View Article and Find Full Text PDF

PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.

Research (Wash D C)

September 2025

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by a high propensity for metastasis, poor prognosis, and limited treatment options. Research has demonstrated a substantial correlation between the expression of protein arginine N-methyltransferase 1 (PRMT1) and enhanced proliferation, metastasis, and poor outcomes in TNBC. However, the specific role of PRMT1 in lung metastasis and chemoresistance remains unclear.

View Article and Find Full Text PDF

Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.

Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).

Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.

View Article and Find Full Text PDF

A strategy for targeting tumor-associated hypoxia utilizes reductase enzyme-mediated cleavage to convert biologically inert prodrugs to their corresponding biologically active parent therapeutic agents selectively in areas of pronounced hypoxia. Small-molecule inhibitors of tubulin polymerization represent unique therapeutic agents for this approach, with the most promising functioning as both antiproliferative agents (cytotoxins) and as vascular disrupting agents (VDAs). VDAs selectively and effectively disrupt tumor-associated microvessels, which are typically fragile and chaotic in nature.

View Article and Find Full Text PDF

Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.

View Article and Find Full Text PDF